Nuvasive Inc Stock Price, News & Analysis

NuVasive (NASDAQ: NUVA) announced a study in the Journal of Neurosurgery: Spine, validating the clinical and economic benefits of its synthetic solutions for lateral lumbar fusions. Conducted with 90 patients, the research showed a high effective fusion rate of 97.8% at 12 months using synthetic biologics and porous titanium implants. Attrax Putty and Modulus XLIF are highlighted as cost-effective alternatives to premium-priced biologics, promising significant cost savings for hospitals. This underscores NuVasive's commitment to innovative spine surgery solutions that improve patient outcomes and reduce costs.

On July 18, 2022, NuVasive (NASDAQ: NUVA) announced it will release its second quarter financial results on August 3, 2022, post-market. A conference call to discuss the results will take place at 4:30 PM ET, accessible via specific dial-in numbers or via a live webcast on their Investor Relations page. NuVasive, a leader in spine technology, boasts over $1 billion in net sales, offering innovative surgical solutions across more than 50 countries. For detailed information, visit www.nuvasive.com.

NuVasive (NASDAQ: NUVA) has announced the opening of its Singapore Experience Center, aimed at enhancing surgeon training and education in the Asia-Pacific region. This initiative supports the company's goal of global expansion and commitment to less-invasive spine surgery technologies. The center will provide educational resources, including a dedicated Pulse demonstration site and advanced training rooms. Chris Barry, CEO, emphasized that this investment is crucial for scaling their operations in international markets while promoting effective surgical practices.

NuVasive (NASDAQ: NUVA) reported a strong first quarter of 2022, with net sales reaching $290.8 million, reflecting a 7.2% year-over-year increase. The company saw a 9.1% rise in constant currency, driven by higher procedure volumes in the U.S. and robust international performance. GAAP diluted earnings per share improved to $0.35 compared to a loss of ($0.15) in the prior year. NuVasive updated its 2022 guidance, raising the lower end of its net sales growth forecast to 6.0%-8.0%.

Blue Spark Technologies Inc. has appointed John DeFord, Ph.D., to its board of directors, effective April 13, 2022, increasing the board size to five members. Dr. DeFord, with over 30 years in medical device leadership, aims to enhance the company’s TempTraq® platform, a remote patient monitoring solution. His extensive experience includes roles at Becton, Dickinson and Company and Cook Incorporated. The company is enthusiastic about Dr. DeFord's contributions as it seeks to establish TempTraq® as the new standard in remote monitoring.

NuVasive, Inc. (NASDAQ: NUVA) announced a significant achievement with over 100 peer-reviewed publications on its Precice^® System, which addresses limb lengthening and reconstruction. Introduced in 2011, the Precice System allows non-invasive limb lengthening and has been utilized in around 15,000 procedures across 45 countries. The technology is recognized for its benefits in reducing pain and complications in patients.

The press release highlights the collaboration between global researchers, emphasizing the adoption of Precice as a standard of care in modern orthopedic practices.

NuVasive (NASDAQ: NUVA) announced the publication of peer-reviewed results from its two-level FDA Investigational Device Exemption study of the Simplify® Cervical Disc. The study, published in the Journal of Neurosurgery: Spine, highlights the disc's superior success rate compared to anterior cervical discectomy and fusion (ACDF) at the 24-month follow-up. Key findings indicate improved disability scores, reduced rates of subsequent surgeries, and better overall outcomes for patients using the Simplify Disc. This evidence supports its position as the leading technology in cervical total disc replacement.

NuVasive, Inc. (NASDAQ: NUVA) announced the upcoming release of its first quarter 2022 financial results on May 4, 2022, after market close. A conference call to discuss the results will follow at 4:30 p.m. ET. Interested parties can access the call via dial-in or webcast. NuVasive specializes in spine technology, offering minimally disruptive surgical solutions and generating over $1 billion in net sales across more than 50 countries. However, the company cautions that its forward-looking statements may involve risks and uncertainties affecting future performance.

NuVasive, Inc. (NASDAQ: NUVA) reported financial results for Q4 and full year 2021, showing net sales of $302.1 million in Q4, up 3.5%, and net sales of $1.139 billion for 2021, an 8.4% increase. However, the company faced significant challenges, with a GAAP net loss of $36.7 million in Q4 and $64.1 million for the year. Non-GAAP diluted EPS was $0.40 for Q4 and $1.68 for 2021. Looking forward, NuVasive expects net sales growth of 5.0%-8.0% in 2022, with guidance for diluted EPS of $0.71-$1.01.